OBI Pharma Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Public

  • Employees
  • 40

Employees

  • Stock Symbol
  • 4174

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.72
  • (As of Monday Closing)

OBI Pharma General Information

Description

OBI Pharma Inc is part of the healthcare sector. The company and its subsidiaries are engaged in new drug research. Its focus is on the unmet medical need in challenging diseases throughout the world, such as cancer. OBI strives to improve health and the quality of life through cost-effective therapeutics. The group has four reportable segments, which are the anti-cancer new drug segment, bispecific monoclonal antibody new drug segment, botulinum toxin new drug segment, and CDMO segment.

Contact Information

Website
www.obipharma.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Suite W1907 19th Floor
  • No. 3, Park Street Nankang Software Park
  • Taipei, 115-03
  • Taiwan
+886 02
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
ROCO
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Suite W1907 19th Floor
  • No. 3, Park Street Nankang Software Park
  • Taipei, 115-03
  • Taiwan
+886 02

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OBI Pharma Stock Performance

As of 20-Jan-2025, OBI Pharma’s stock price is $1.72. Its current market cap is $451M with 263M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.72 $1.69 $1.66 - $2.91 $451M 263M 746K -$0.29

OBI Pharma Financials Summary

As of 30-Sep-2024, OBI Pharma has a trailing 12-month revenue of $2.18M.

In Thousands,
USD 		TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 543,553 469,085 405,623 760,197
Revenue 2,176 1,334 158 672
EBITDA (66,234) (35,688) (57,654) (54,702)
Net Income (65,906) (33,597) (54,211) (54,776)
Total Assets 126,530 182,371 216,239 162,043
Total Debt 16,672 16,306 8,054 10,583
Public Fundamental Data provided by Morningstar, Inc. disclaimer

OBI Pharma Patents

  • 218

    Total Documents Applications and Grants

  • Total Patents Families

  • 133

    Granted

  • 65

    Pending

  • Expiring in next 12 mo

OBI Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021443620-A1 Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor Pending 28-Apr-2021
CA-3216896-A1 Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor Pending 28-Apr-2021
EP-4329745-A1 Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor Pending 28-Apr-2021
US-20240216401-A1 Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor Pending 28-Apr-2021
CA-3203644-A1 Use of akr1c3-activated compound Pending 26-Feb-2021 A61K31/675
To view OBI Pharma’s complete patent history, request access »

OBI Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OBI Pharma Investments & Acquisitions (2)

OBI Pharma’s most recent deal was a Merger/Acquisition with AP Biosciences. The deal was made on 29-Dec-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
AP Biosciences 29-Dec-2017 Merger/Acquisition Drug Discovery
Threshold Pharmaceuticals (OBI-3424 small molecule Prodrug) 01-Jun-2017 Corporate Asset Purchase Buildings and Property
To view OBI Pharma’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

OBI Pharma ESG

Risk Overview

Risk Rating

Updated November, 21, 2023

24.39 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,104

Rank

Percentile

Pharmaceuticals

Industry

of 851

Rank

Percentile

Biotechnology

Subindustry

of 367

Rank

Percentile

To view OBI Pharma’s complete esg history, request access »

OBI Pharma FAQs

  • When was OBI Pharma founded?

    OBI Pharma was founded in 2002.

  • Where is OBI Pharma headquartered?

    OBI Pharma is headquartered in Taipei, Taiwan.

  • What is the size of OBI Pharma?

    OBI Pharma has 40 total employees.

  • What industry is OBI Pharma in?

    OBI Pharma’s primary industry is Biotechnology.

  • Is OBI Pharma a private or public company?

    OBI Pharma is a Public company.

  • What is OBI Pharma’s stock symbol?

    The ticker symbol for OBI Pharma is 4174.

  • What is the current stock price of OBI Pharma?

    As of 20-Jan-2025 the stock price of OBI Pharma is $1.72.

  • What is the current market cap of OBI Pharma?

    The current market capitalization of OBI Pharma is $451M.

  • What is OBI Pharma’s current revenue?

    The trailing twelve month revenue for OBI Pharma is $2.18M.

  • What is OBI Pharma’s annual earnings per share (EPS)?

    OBI Pharma’s EPS for 12 months was -$0.29.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »